After reviewing its strategic position in the inflammatory diseases space after discontinuing anti-IL-20 for the treatment of rheumatoid arthritis, Novo Nordisk (NYSE:NVO) decides to discontinue its R&D efforts in the area. EVP and CSO Mads Krogsgaard Thomsen says, "The discontinuation of anti-IL-20 delays our earliest possible entrance into the market for anti-inflammatory therapeutics to the late 2020s. Significant unmet opportunities remain within diabetes, including prevention, obesity and diabetes complications. We have therefore decided to further increase our R&D efforts within diabetes which is our main business area."
The company's decision will affect ~400 employees. Management believes it will be possible to offer ~200 other jobs within the organization.